AM Pharma

OverviewSuggest Edit

AM-Pharma, a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein-derived peptides, as well as molecules that naturally occur in the human body. 
TypePrivate
Founded2001
HQBunnik, NL
Websiteam-pharma.com

Latest Updates

Employees (est.) (Sept 2021)51(-3%)
Cybersecurity ratingBMore

Key People/Management at AM Pharma

Erik van den Berg

Erik van den Berg

Chief Executive Officer
Juliane Bernholz

Juliane Bernholz

Chief Operating Officer
Jacques Arend

Jacques Arend

VP Clinical Development
Maarten Kraan

Maarten Kraan

Chief Medical Officer
Wolfgang Meder

Wolfgang Meder

VP Regulatory Affairs & Quality Management
Laetitia Szaller

Laetitia Szaller

General Counsel & VP Business Development
Show more

AM Pharma Office Locations

AM Pharma has offices in Bunnik and Utrecht
Bunnik, NL (HQ)
Rumpsterweg 6
Utrecht, NL
Stadsplateau 6
Show all (2)

AM Pharma Financials and Metrics

Summary Metrics

Founding Date

2001

AM Pharma total Funding

$210.3 m

AM Pharma latest funding size

$23.99 m

Time since last funding

a year ago

AM Pharma investors

AM Pharma's latest funding round in March 2020 was reported to be $24 m. In total, AM Pharma has raised $210.3 m
Show all financial metrics

AM Pharma Cybersecurity Score

Cybersecurity ratingPremium dataset

B

83/100

SecurityScorecard logo

AM Pharma Online and Social Media Presence

Embed Graph

AM Pharma Blogs

AM-Pharma Appoints Lars Boesgaard as Chief Financial Officer and Establishes U.S. Affiliate AM-Pharma Inc.

Utrecht, The Netherlands, 15 September, 2021 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced the appointment of Lars R. Boesgaard as Chief Financial Officer (CFO), effective immediately. Mr. Boesgaard’s career spans 25 years and …

AM-Pharma and Kyowa Kirin Sign Exclusive License Agreement for Commercialization of Ilofotase Alfa in Japan

AM-Pharma to receive EUR 20 million upfront payment, and EUR 30 million related to milestones prior to regulatory submission, and up to EUR 195 million upon submission, NHI price listing and sales milestone payments bringing the overall deal value to EUR 245 million. Kyowa Kirin gains exclusive righ…

AM-Pharma Appoints Mark Altmeyer as Chairman of its Supervisory Board

Utrecht, The Netherlands, 6 July, 2021 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced the appointment of Mark Altmeyer, MBA, as Chairman of its Supervisory Board. Mr. Altmeyer is a highly successful biopharma executive with deca…

AM-Pharma Enrolls First Patient in Japan for Ongoing Phase III SA-AKI Pivotal REVIVAL Trial

Utrecht, The Netherlands, 1 July 2021 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced the enrollment of the first patient in Japan as part of its ongoing global pivotal Phase III trial, called REVIVAL. The REVIVAL study is evalua…

AM-Pharma Appoints Martijn Negen as VP Commercial Strategy

Utrecht, The Netherlands, 15 June 2021 – AM-Pharma B.V., an emerging leader focused on  developing therapeutics for severe medical conditions, today announced the appointment of Martijn Negen, MSc, MBA, as Vice President for Commercial Strategy. Martijn Negen has over 20 years of experience in pharm…

AM-Pharma Announces Enrollment and Financing of COVID-19 Cohort in Phase III REVIVAL Trial

– First patients with COVID-19 enrolled in the REVIVAL Phase III study – COVID-19 patients with sepsis-associated acute kidney injury will be included in an exploratory cohort in the pivotal trial enrolling up to 1,600 SA-AKI patients overall – RVO, an agency of the Dutch Ministry of Economic Affair…
Show more

AM Pharma Frequently Asked Questions

  • When was AM Pharma founded?

    AM Pharma was founded in 2001.

  • Who are AM Pharma key executives?

    AM Pharma's key executives are Erik van den Berg, Juliane Bernholz and Jacques Arend.

  • How many employees does AM Pharma have?

    AM Pharma has 51 employees.

  • Who are AM Pharma competitors?

    Competitors of AM Pharma include Neopharmed Gentili, Macopharma and Heron Therapeutics.

  • Where is AM Pharma headquarters?

    AM Pharma headquarters is located at Rumpsterweg 6, Bunnik.

  • Where are AM Pharma offices?

    AM Pharma has offices in Bunnik and Utrecht.

  • How many offices does AM Pharma have?

    AM Pharma has 2 offices.